Thomas J Vogl, Parviz Farshid, Nagy N N Naguib, Stefan Zangos, Boris Bodelle, Jijo Paul, Emannuel C Mbalisike, Martin Beeres, Nour-Eldin A Nour-Eldin
{"title":"肝细胞癌的消融治疗:射频与微波消融的比较研究。","authors":"Thomas J Vogl, Parviz Farshid, Nagy N N Naguib, Stefan Zangos, Boris Bodelle, Jijo Paul, Emannuel C Mbalisike, Martin Beeres, Nour-Eldin A Nour-Eldin","doi":"10.1007/s00261-015-0355-6","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>The aim of the study is to retrospectively evaluate and compare the therapeutic response of Radiofrequency (RF) and Microwave (MW) ablation therapy of hepatocellular carcinoma (HCC).</p><p><strong>Materials and methods: </strong>53 consecutive patients (42 males, 11 females; mean age 59 years, range: 40-68, SD: 4.2) underwent CT-guided percutaneous RF and MW ablation of 68 HCC liver lesions. The morphologic tumor response (number, location and size) was evaluated by magnetic resonance imaging. The follow-up protocol was 24 h post-ablation then within 3 monthly intervals post-ablation in the first year and 6 monthly intervals thereafter.</p><p><strong>Results: </strong>Complete therapeutic response was noted in 84.4% (27/32) of lesions treated with RFA and in 88.9% (32/36) of lesions treated with MW ablation (P = 0.6). Complete response was achieved in all lesions ≤2.0 cm in diameter in both groups. There was no significant difference in rates of residual foci of HCC lesions between RF and MW ablation groups (P = 0.15, Log-rank test). Recurrence rate for 3, 6, 9, and 12 months in patients with HCC who underwent RF ablation compared with MW ablation were 6.3%, 3.1%, 3.1% versus 0%, 5.6%, 2.8%, and 2.8%. Progression-Free Survival rates for treated patients with RF ablation of 1, 2, and 3 years were 96.9%, 93.8%, and 90.6% and treated with MW ablation therapy were 97.2%, 94.5%, and 91.7, respectively (P = 0.98).</p><p><strong>Conclusion: </strong>In conclusion, RF and MW ablation therapy showed no significant difference in the treatment of HCC regarding the complete response, rates of residual foci of untreated disease, and recurrence rate.</p>","PeriodicalId":7014,"journal":{"name":"Abdominal Imaging","volume":"40 6","pages":"1829-37"},"PeriodicalIF":0.0000,"publicationDate":"2015-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/s00261-015-0355-6","citationCount":"85","resultStr":"{\"title\":\"Ablation therapy of hepatocellular carcinoma: a comparative study between radiofrequency and microwave ablation.\",\"authors\":\"Thomas J Vogl, Parviz Farshid, Nagy N N Naguib, Stefan Zangos, Boris Bodelle, Jijo Paul, Emannuel C Mbalisike, Martin Beeres, Nour-Eldin A Nour-Eldin\",\"doi\":\"10.1007/s00261-015-0355-6\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose: </strong>The aim of the study is to retrospectively evaluate and compare the therapeutic response of Radiofrequency (RF) and Microwave (MW) ablation therapy of hepatocellular carcinoma (HCC).</p><p><strong>Materials and methods: </strong>53 consecutive patients (42 males, 11 females; mean age 59 years, range: 40-68, SD: 4.2) underwent CT-guided percutaneous RF and MW ablation of 68 HCC liver lesions. The morphologic tumor response (number, location and size) was evaluated by magnetic resonance imaging. The follow-up protocol was 24 h post-ablation then within 3 monthly intervals post-ablation in the first year and 6 monthly intervals thereafter.</p><p><strong>Results: </strong>Complete therapeutic response was noted in 84.4% (27/32) of lesions treated with RFA and in 88.9% (32/36) of lesions treated with MW ablation (P = 0.6). Complete response was achieved in all lesions ≤2.0 cm in diameter in both groups. There was no significant difference in rates of residual foci of HCC lesions between RF and MW ablation groups (P = 0.15, Log-rank test). Recurrence rate for 3, 6, 9, and 12 months in patients with HCC who underwent RF ablation compared with MW ablation were 6.3%, 3.1%, 3.1% versus 0%, 5.6%, 2.8%, and 2.8%. Progression-Free Survival rates for treated patients with RF ablation of 1, 2, and 3 years were 96.9%, 93.8%, and 90.6% and treated with MW ablation therapy were 97.2%, 94.5%, and 91.7, respectively (P = 0.98).</p><p><strong>Conclusion: </strong>In conclusion, RF and MW ablation therapy showed no significant difference in the treatment of HCC regarding the complete response, rates of residual foci of untreated disease, and recurrence rate.</p>\",\"PeriodicalId\":7014,\"journal\":{\"name\":\"Abdominal Imaging\",\"volume\":\"40 6\",\"pages\":\"1829-37\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2015-08-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1007/s00261-015-0355-6\",\"citationCount\":\"85\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Abdominal Imaging\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1007/s00261-015-0355-6\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Abdominal Imaging","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s00261-015-0355-6","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Ablation therapy of hepatocellular carcinoma: a comparative study between radiofrequency and microwave ablation.
Purpose: The aim of the study is to retrospectively evaluate and compare the therapeutic response of Radiofrequency (RF) and Microwave (MW) ablation therapy of hepatocellular carcinoma (HCC).
Materials and methods: 53 consecutive patients (42 males, 11 females; mean age 59 years, range: 40-68, SD: 4.2) underwent CT-guided percutaneous RF and MW ablation of 68 HCC liver lesions. The morphologic tumor response (number, location and size) was evaluated by magnetic resonance imaging. The follow-up protocol was 24 h post-ablation then within 3 monthly intervals post-ablation in the first year and 6 monthly intervals thereafter.
Results: Complete therapeutic response was noted in 84.4% (27/32) of lesions treated with RFA and in 88.9% (32/36) of lesions treated with MW ablation (P = 0.6). Complete response was achieved in all lesions ≤2.0 cm in diameter in both groups. There was no significant difference in rates of residual foci of HCC lesions between RF and MW ablation groups (P = 0.15, Log-rank test). Recurrence rate for 3, 6, 9, and 12 months in patients with HCC who underwent RF ablation compared with MW ablation were 6.3%, 3.1%, 3.1% versus 0%, 5.6%, 2.8%, and 2.8%. Progression-Free Survival rates for treated patients with RF ablation of 1, 2, and 3 years were 96.9%, 93.8%, and 90.6% and treated with MW ablation therapy were 97.2%, 94.5%, and 91.7, respectively (P = 0.98).
Conclusion: In conclusion, RF and MW ablation therapy showed no significant difference in the treatment of HCC regarding the complete response, rates of residual foci of untreated disease, and recurrence rate.